coronavirus vaccine
Heart reaction probed as possible rare vaccine link in teens
Health authorities are trying to determine whether heart inflammation that can occur along with many types of infections could also be a rare side effect in teens and young adults after the second dose of COVID-19 vaccine.
An article on seven U.S. teen boys in several states, published online Friday in Pediatrics, is among the latest reports of heart inflammation discovered after COVID-19 vaccination, though a link to the vaccine has not been proven.
The boys, aged 14 to 19, received Pfizer shots in April or May and developed chest pain within a few days. Heart imaging tests showed a type of heart muscle inflammation called myocarditis.
Read:US to swiftly boost global vaccine sharing, Biden announces
None were critically ill. All were healthy enough to be sent home after two to six days in the hospital and are doing ’’doing pretty well,” said Dr. Preeti Jaggi, an Emory University infectious disease specialist who co-authored the report.
She said more follow-up is needed to determine how the seven fare but that it’s likely the heart changes were temporary.
Only one of the seven boys in the Pediatrics report had evidence of a possible previous COVID-19 infection and doctors determined none of them had a rare inflammatory condition linked with the coronavirus.
The cases echo reports from Israel in young men diagnosed after receiving Pfizer shots.
The U.S. Centers for Disease Control and Prevention alerted doctors last month that it was monitoring a small number of reports of heart inflammation in teens and young adults after the mRNA vaccines, the kind made by Pfizer and Moderna.
Read:Vaccine maker Serum seeks indemnity protection in India
The CDC hasn’t determined if there’s really a link to the shots, and continues to urge that everyone 12 and older get vaccinated against COVID-19, which is far riskier than the vaccine. The Pfizer vaccine is available to those as young as 12; the Moderna shot remains cleared only for adult use.
This kind of heart inflammation can be caused by a variety of infections, including a bout of COVID-19, as well as certain medications -- and there have been rare reports following other types of vaccinations.
Authorities will have to tease out whether cases following COVID-19 vaccination are occurring more often than that expected “background rate.”
For now, the CDC says most patients were male, reported symptoms after the second dose, and their symptoms rapidly improved.
“I think we’re in the waiting period where we need to see whether this is cause-and-effect or not,” said John Grabenstein of the Immunization Action Coalition, a former director of the Defense Department’s immunization program.
Read: Free beer, other new incentives for Biden’s ‘vaccine sprint’
A Pediatrics editorial noted that among U.S. children under age 18, there have been over 4 million COVID-19 cases, more than 15,000 hospitalizations and at least 300 deaths.
It said the heart inflammation cases warrant more investigation but added that ’’the benefits of vaccination against this deadly and highly transmissible disease clearly far outweigh any potential risks.”
Editorial co-author Dr. Yvonne Maldonado, head of an American Academy of Pediatrics infectious diseases committee, is involved in Pfizer vaccine studies, including a COVID-19 vaccine study in children.
Bangladesh seeks TRIPS waiver to ramp up Covid vaccine production
Bangladesh has called for a temporary waiver from certain obligations under the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the production of vaccines, medicines and other health technologies to effectively respond to the pandemic.
Bangladesh made the demand in the just concluded 74th virtual session of the World Health Assembly (WHA) held in Geneva.
Read: US unveils strategy for global vaccine sharing with Bangladesh, India on list
Intellectual property is currently a barrier to swiftly scaling up and diversifying the production of Covid-19 health products, including vaccines.
Bangladesh said the pharmaceutical industries across the developing countries, including Bangladesh, capable of producing vaccines, therapeutics, diagnostics and other medical equipment should get licenses as well as technology and technical know-how to produce the vaccines and health technologies for Covid-19 and those items should be provided to other developing countries free of cost.
Besides, Bangladesh highlighted the timely and swift actions taken by the government of Sheikh Hasina, including health measures and stimulus packages, to combat the socio-economic impacts posed by the pandemic.
A Bangladesh delegation, led by Zahid Maleque, Minister for Health and Family Welfare, and in direct collaboration with the Permanent Mission of Bangladesh in Geneva, attended the virtual WHA, said the Ministry of Foreign Affairs on Friday.
Read:COVAX Facility: Japan to provide 30mn vaccine doses to other countries
This year, the Assembly mainly focused on the production, supply and equitable distribution of vaccines to address the Covid-19 crisis.
US unveils strategy for global vaccine sharing with Bangladesh, India on list
The US Administration has unveiled its strategy for global vaccine sharing through COVAX, keeping Bangladesh and India on the list.
The Biden-Harris Administration on Thursday announced an allocation plan for the first 25 million doses to be shared globally.
Approximately 7 million doses will be shared in Asia covering countries and entities, including Bangladesh, India, Nepal, Pakistan, Sri Lanka, Afghanistan, the Maldives, Malaysia, the Philippines, Vietnam, Indonesia, Thailand, Laos, Papua New Guinea, Taiwan, and the Pacific Islands, according to White House.
As they continue to fight the Covid-19 pandemic at home and work to end the pandemic worldwide, US President Joe Biden has promised that the United States will be an arsenal of vaccines for the world.
Also read: COVAX Facility: Japan to provide 30mn vaccine doses to other countries
To do that, the administration will pursue several additional measures beyond their robust funding for COVAX: Donating from the US vaccine supply to the world and encouraging other nations to do the same, working with US manufacturers to increase vaccine production for the rest of the world, and help more countries expand their own capacity to produce vaccines, including through support for global supply chains.
This vaccine strategy is a vital component of our overall global strategy to lead the world in the fight to defeat Covid-19, including emergency public health assistance and aid to stop the spread and building global public health capacity and readiness to beat not just this pandemic, but the next one.
The administration announced its framework for sharing at least 80 million US vaccine doses globally by the end of June and the plan for the first 25 million doses.
The United States will share vaccines in service of ending the pandemic globally.
Also read: Vaccine maker Serum seeks indemnity protection in India
The administration announced its framework for sharing these 80 million US vaccine doses worldwide.
Vaccine maker Serum seeks indemnity protection in India
Serum Institute has sought indemnity against legal proceedings linked to the use of its vaccines in India as well as the government's nod to produce Russian Covid-19 jab Sputnik V in this country.
"Not just Serum Institute of India (SII), all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it," a company official told the local media on Thursday.
Read:India's COVID-19 tally rises to 28,441,986
Serum's demand comes in the wake of media reports that Prime Minister Narendra Modi's government is planning to grant legal protection to foreign Covid vaccine makers Pfizer and Moderna.
The vaccine maker has also sought permission from the country's drugs controller for a test licence to manufacture Sputnik V shots in India.
"SII put up an application to the Drugs Controller General of India on Wednesday, seeking permission to manufacture Sputnik V in India," another company official told the local media.
Read: India to start trials on safety, efficacy of mixing Covid vaccine doses
Slow to start, China mobilizes to vaccinate at headlong pace
In the span of just five days last month, China gave out 100 million shots of its COVID-19 vaccines.
After a slow start, China is now doing what virtually no other country in the world can: harnessing the power and all-encompassing reach of its one-party system and a maturing domestic vaccine industry to administer shots at a staggering pace. The rollout is far from perfect, including uneven distribution, but Chinese public health leaders now say they’re hoping to inoculate 80% of the population of 1.4 billion by the end of the year.
As of Tuesday, China had given out more than 680 million doses — with nearly half of those in May alone. China’s total is roughly a third of the 1.9 billion shots distributed globally, according to Our World in Data, an online research site.
Read: China reports human case of H10N3 bird flu, a possible first
The call to get vaccinated comes from every corner of society. Companies offer shots to their employees, schools urge their students and staffers, and local government workers check on their residents.
That pressure underscores both the system’s strength, which makes it possible to even consider vaccinating more than a billion people this year, but also the risks to civil liberties — a concern the world over but one that is particularly acute in China, where there are few protections.
“The Communist Party has people all the way down to every village, every neighborhood,” said Ray Yip, former country director for the Gates Foundation in China and a public health expert. “That’s the draconian part of the system, but it also gives very powerful mobilization.”
China is now averaging about 19 million shots per day, according to Our World in Data’s rolling seven-day average. That would mean a dose for everyone in Italy about every three days. The United States, with about one-quarter of China’s population, reached around 3.4 million shots per day in April when its drive was at full tilt.
It’s still unclear how many people in China are fully vaccinated — which can mean anywhere from one to three doses of the vaccines in use — as the government does not publicly release that data.
Zhong Nanshan, the head of a group of experts attached to the National Health Commission and a prominent government doctor, said on Sunday that 40% of the population has received at least one dose, and the aim was to get that percentage fully vaccinated by the end of the month.
In Beijing, the capital, 87% of the population has received at least one dose. Getting a shot is as easy as walking into one of hundreds of vaccination points found all across the city. Vaccination buses are parked in high foot-traffic areas, including in the city center and at malls.
Read: China easing birth limits further to cope with aging society
But Beijing’s abundance is not shared with the rest of the country, and local media reports and complaints on social media show the difficulty of getting an appointment elsewhere.
“I started lining up that day at 9 in the morning, until 6 p.m., only then did I get the shot. It was exhausting,” Zhou Hongxia, a resident of Lanzhou, in northwestern Gansu province, explained recently. “When I left, there were still people waiting.”
Zhou’s husband hasn’t been so lucky and has yet to get a shot. When they call the local hotlines, they are told simply to wait.
Central government officials on Monday said they’re working to ensure supply is more evenly distributed.
Before the campaign ramped up in recent weeks, many people were not in a rush to get vaccinated as China has kept the virus, which first flared in the country, at bay in the past year with strict border controls and mandatory quarantines. It has faced small clusters of infections from time to time, and is currently managing one in the southern city of Guangzhou.
Although there are distribution issues, it is unlikely that Chinese manufacturers will have problems with scale, according to analysts and those who have worked in the industry.
Sinovac and Sinopharm, which make the majority of the vaccines being distributed in China, have both aggressively ramped up production, building brand new factories and repurposing existing ones for COVID-19. Sinovac’s vaccine and one of the two Sinpharm makes have received an emergency authorization for use from the World Health Organization, but the companies, particularly Sinopharm, have faced criticism for their lack of transparency in sharing their data.
“What place in the world can compare with China on construction? How long did it take our temporary hospitals to be built?” asked Li Mengyuan, who leads pharmaceutical research at Western Securities, a financial firm. China built field hospitals at the beginning of the pandemic in just days.
Read: China, Philippines swap protests over Manila-occupied island
Sinovac has said it has doubled its production capacity to 2 billion doses a year, while Sinopharm has said it can make up to 3 billion doses a year. But Sinopharm has not disclosed recent numbers of how many doses it actually has made, and a spokesman for the company did not respond to a request for comment. Sinovac has produced 540 million doses this year as of late May, the company said on Friday.
Government support has been crucial for vaccine developers every step of the way — as it has in other countries — but, as with everything, the scope and scale in China is different.
Yang Xiaoming, chairman of Sinopharm’s China National Biotec Group, recounted to state media recently how the company initially needed to borrow lab space from a government research center while it was working on a vaccine.
“We sent our samples over, there was no need to discuss money, we just did it,” he said.
Chinese vaccine companies also largely do not rely on imported products in the manufacturing process. That’s an enormous benefit at a time when many countries are scrambling for the same materials and means China can likely avoid what happened to the Serum Institute of India, whose production was hobbled because of dependence on imports from the U.S. for certain ingredients.
But as the availability of the vaccine increases so, too, can the pressure to take it.
In Beijing, one researcher at a university said the school’s Communist Party cell calls him once a month to ask him if he has gotten vaccinated yet, and offers to help him make an appointment.
Read:China may buckle down to reunify Taiwan after crackdown on Hong Kong
He has so far declined to get a shot because he would prefer the Pfizer vaccine, saying he trusts its data. He spoke on condition of anonymity because of concerns he could face repercussions at his job at a government university for publicly questioning the Chinese vaccines.
China has not yet approved Pfizer for use, and the researcher is not sure how long he can hold out — although the government has, for now, cautioned against making vaccines mandatory outright.
“They don’t have to say it is mandatory,” Yip, the public health expert, said. “They’re not going to announce that it’s required to have the vaccine, but they can put pressure on you.”
Free beer, other new incentives for Biden’s ‘vaccine sprint’
Dangling everything from sports tickets to a free beer, President Joe Biden is looking for that extra something — anything — that will get people to roll up their sleeves for COVID-19 shots when the promise of a life-saving vaccine by itself hasn’t been enough.
Biden on Wednesday announced a “month of action” to urge more Americans to get vaccinated before the July 4 holiday, including an early summer sprint of incentives and a slew of new steps to ease barriers and make getting shots more appealing to those who haven’t received them. He is closing in on his goal of getting 70% of adults at least partially vaccinated by Independence Day — essential to his aim of returning the nation to something approaching a pre-pandemic sense of normalcy this summer.
“The more people we get vaccinated, the more success we’re going to have in the fight against this virus,” Biden said from the White House. He predicted that with more vaccinations, America will soon experience “a summer of freedom, a summer of joy, a summer of get togethers and celebrations. An All-American summer.”
The Biden administration views June as “a critical month in our path to normal,” Courtney Rowe, the director of strategic communications and engagement for the White House COVID-19 response team, told the AP.
Read: Biden’s $6T budget: Social spending, taxes on business
Biden’s plan will continue to use public and private-sector partnerships, mirroring the “whole of government” effort he deployed to make vaccines more widely available after he took office. The president said he was “pulling out all the stops” to drive up the vaccination rate.
Among those efforts is a promotional giveaway announced Wednesday by Anheuser-Busch, saying it will “buy Americans 21+ a round of beer” once Biden’s 70% goal is met.
“Get a shot and have a beer,” Biden said, advertising the promotion even though he himself refrains from drinking alcohol.
Additionally, the White House is partnering with early childhood centers such as KinderCare, Learning Care Group, Bright Horizons and more than 500 YMCAs to provide free childcare coverage for Americans looking for shots or needing assistance while recovering from side effects.
The administration is also launching a new partnership to bring vaccine education and even doses to more than a thousand Black-owned barbershops and beauty salons, building on a successful pilot program in Maryland.
They’re the latest vaccine sweeteners, building on other incentives like cash giveaways, sports tickets and paid leave, to keep up the pace of vaccinations.
“The fact remains that despite all the progress, those who are unvaccinated still remain at risk of getting seriously ill or dying or spreading the disease to others,” said Rowe.
Read: Biden orders more intel investigation of COVID-19 origin
Aiming to make injections even more convenient, Biden is announcing that many pharmacies are extending their hours this month — and thousands will remain open overnight on Fridays. The White House is also stepping up its efforts to help employers run on-site vaccination clinics.
Biden will also announce that he is assigning Vice President Kamala Harris to lead a “We Can Do This” vaccination tour to encourage shots. It will include first lady Jill Biden, second gentleman Doug Emhoff and Cabinet officials. Harris’ travel will be focused on the South, where vaccination rates are among the lowest in the country, while other officials will travel to areas of the Midwest with below average rates.
To date 62.9% of the adult U.S. population have received at least one dose of a COVID-19 vaccine and 133.9 million are fully vaccinated. The rate of new vaccinations has slowed to an average below 555,000 per day, down from more than 800,000 when incentives like lotteries were announced, and down from a peak of nearly 2 million per day in early April when demand for shots was much higher.
The lengths to which the U.S. is resorting to convince Americans to take a shot stands in contrast to much of the world, where vaccines are far less plentiful. Facing a mounting U.S. surplus, the Biden administration is planning to begin sharing 80 million doses with the world this month.
“All over the world people are desperate to get a shot that every American can get at their neighborhood drugstore,” Biden said.
“Incentives can work, and I think the White House’s focus on making vaccination the easy and convenient choice is important,” said Dr. Leana Wen, an emergency physician, public health professor at George Washington University and former Baltimore health commissioner.
“It’s the height of American exceptionalism that we are having to beg people to get a life-saving vaccine, when healthcare workers and vulnerable people around the world are dying because they can’t get access to it,” she added.
Read: Face to face: June summit for Biden, Putin as tensions rise
Thanks to the vaccinations, the rate of cases and deaths in the U.S. are at their lowest since the beginning of the pandemic last March, averaging under 16,000 new cases and under 400 deaths per day.
As part of the effort to drive Americans to get shots, the White House is borrowing some tools from political campaigns, including phone banks, door-knocking and texting. The administration says more than 1,000 such events will be held this weekend alone. Additionally, it is organizing competitions between cities and colleges to drive up vaccination rates.
Other new incentives include a $2 million commitment from DoorDash to provide gift cards to community health centers to be used to drive people to get vaccinated. CVS launched a sweepstakes with prizes including free cruises and Super Bowl tickets. Major League Baseball will host on-site vaccine clinics and ticket giveaways at games. And Kroger will give $1 million to a vaccinated person each week this month and dozens of people free groceries for the year.
The fine print on the Anheuser-Busch promotion reveals the benefits to the sponsoring company, which will collect consumer data and photos through its website to register for the $5 giveaway. The company says it will hand out credits to however many people qualify.
Sinovac vaccine restores a Brazilian city to near normal
Just one COVID-19 patient is in critical condition at the Dr. Geraldo Cesar Reis clinic in Serrana, a city of almost 46,000 in Sao Paulo state’s countryside. The 63-year-old woman rejected the vaccine that was offered to every adult resident of Serrana as part of a trial.
Doctors say the woman was awaiting one of Pfizer’s shots, which remain scarce in Brazil. But she is an outlier here. Most adults rolled up their sleeves when offered the vaccine made by the Chinese pharmaceutical company Sinovac, and the experiment has transformed the community into an oasis of near normalcy in a country where many communities continue to suffer.
Doctors who treated COVID-19 in Serrana have seen their patient loads evaporate. They now help colleagues with other diseases and recently started eating lunch at home. Life has returned to the streets: Neighbors chat and families have weekend barbecues. Outsiders who previously had no reason to set foot in Serrana are arriving for haircuts and restaurant outings.
Read:In Brazil’s Amazon, rivers rise to record levels
“We’re now as full as we used to be,” Rogério Silva, a staffer at a store for cheap refreshments and snacks, said in an interview. “Weeks ago, people wouldn’t form a line in here, wouldn’t eat in, and I wouldn’t let them use the bathroom. Now it’s back.”
The success story emerged as other population centers keep struggling with the virus, enduring rising infections and new government-imposed restrictions. Meanwhile, the vaccine appeared headed for wider use. The World Health Organization on Tuesday granted emergency use authorization to the Sinovac shot for people 18 and over, the second such authorization it has granted to a Chinese company.
The experiment known as “Project S” lasted four months and tested Sinovac’s shot in real-world conditions. The preliminary results made public Monday suggest the pandemic can be controlled if three-quarters of the population is fully vaccinated with Sinovac, said Ricardo Palacios, a director at Sao Paulo state’s Butantan Institute and coordinator of the study, which was not peer-reviewed.
“The most important result was understanding that we can control the pandemic even without vaccinating the entire population,” Palacios said.
The results offer hope to hundreds of millions of people, especially in developing nations. Egypt, Pakistan, Indonesia, Zimbabwe and others are likewise reliant on the Chinese shot, which is cheaper than vaccines from Pfizer and Moderna.
The city’s population was split into four geographic areas regardless of age and gender, and most adults received two shots by the end of April. Results released Monday showed that the pandemic was controlled after three of the areas had been vaccinated. It was not clear if vaccine uptake was the same in each area.
Serrana saw vast improvements: Deaths fell by 95%, hospitalizations by 86% and symptomatic cases by 80%.
The project “shows the protection exists and that the vaccine is effective. No doubt,” Gonzalo Vecina, one of the founders of Brazil’s health regulator and a medical school professor, told The Associated Press.
Likewise, Denise Garrett, vice president of the Sabin Vaccine Institute, which advocates for expanding global vaccine access, called the results “good and very encouraging.”
Both Vecina and Garrett said unanswered questions remain and that more data is needed to properly analyze the results, including information about people who got shots but did not develop immunity.
Read:In Argentina, doctors adapt as COVID-19 strains hospitals
The spread of the virus in Serrana slowed while neighboring communities like Ribeirao Preto, just 12 miles west, saw COVID-19 surge. The upswing was largely blamed on more contagious variants.
Hospitals in Ribeirao Preto are so full of COVID-19 patients that the mayor imposed strict shutdown measures last week, including halting public transportation and limiting hours for the city’s 700,000 residents to buy groceries. Some will wait months for their vaccines. Almost all shops are closed, and 95% of intensive-care unit beds are occupied by virus patients.
Elmano Silveira, 54, works at a local drugstore and for the first time wishes he lived in Serrana, which was looked down upon before the vaccination drive.
“My friends from there used to call me all the time. ... Now I’m the one calling them,” Silveira said. “Before the pandemic, we had a big city vibe here. It was really busy. Now it’s like a desert.”
Just months ago, it was Serrana struggling to cope, according to Dr. João Antonio Madalosso Jr. For every patient who recovered in the first three months of 2021, two more arrived in bad shape, he said.
“Then, by the end of January, we heard this project was coming to Serrana. And calmness set in, little by little,” said Madalosso, 32, as he pointed at empty seats of the hospital’s COVID-19 ward. “Just look at this. This is much calmer than Ribeirao Preto and the entire region. The vaccine is no cure, but it is the solution to transform this into a light flu so people can carry on.”
That doesn’t mean Serrana is entirely rid of the virus. Some residents refused to get the shot. Others skipped the second dose or got infected before the vaccine took full effect. A few had prior diseases that prevented them from getting the vaccines.
Brazil’s president, Jair Bolsonaro, has repeatedly cast doubt on the shot’s efficacy. He said last year his administration wouldn’t buy the Chinese vaccine and that he wouldn’t let Brazilians become “guinea pigs.″ His health ministry signed a deal to buy tens of millions of doses only after Brazil’s health regulator approved the shot in January.
Had the government acted sooner, Brazil could have had twice as many Sinovac vaccines by now — 100 million doses, Butantan’s head, Dimas Covas, told a congressional inquiry last week. The shot accounts for half the vaccines made available to date in the country.
Vaccines arrived too late for some of the 463,000 people who have died from COVID-19 in Brazil, which has the world’s second-highest death toll.
The relative return to normal “could be happening all over Brazil if it were not for the delay in vaccinations,” said João Doria, Sao Paulo’s governor and an adversary of Bolsonaro. “These results show there’s only one way to control the pandemic: vaccines, vaccines, vaccines.”
Bolsonaro-fueled skepticism of Sinovac’s shot reached Serrana. It didn’t help that Sao Paulo state’s release of efficacy data was confusing, with Doria initially claiming 78% protection against mild cases on Jan. 7, then revising that five days later to 50.4%, barely above the level required by health authorities.
Carmen da Silva Cunha, 81, has lost friends to the virus, and she got vaccinated despite “a lot of people trying to get into my head regarding the vaccine.”
Read:At least 25 dead during Brazilian police raid in Rio
“Serrana got better, but it could be much more if a lot of people had taken their second shot,” she said in an interview at the hospital, where she sought treatment for a sore throat. She tested negative for COVID-19, and doctors expected her to return home in short order.
Mayor Leo Capitanelli is pleased with results. Standing beside a health screening station on the road into the city, he said people have had only mild and moderate COVID-19 cases in recent weeks. And he boasted about Serrana’s plan to host a music festival for about 5,000 spectators, all vaccinated with Sinovac’s shot.
“This project brought our pride back,” he said. “And it will bring hope for a fresh start next year.”
Japan’s vaccine push ahead of Olympics looks to be too late
It may be too little, too late.
That’s the realization sinking in as Japan scrambles to catch up on a frustratingly slow vaccination drive less than two months before the Summer Olympics, delayed by a year because of the coronavirus pandemic, are scheduled to start.
The Olympics risk becoming an incubator for “a Tokyo variant,” as 15,000 foreign athletes and tens of thousands officials, sponsors and journalists from about 200 countries descend on — and potentially mix with — a largely unvaccinated Japanese population, said Dr. Naoto Ueyama, a physician, head of the Japan Doctors Union.
With infections in Tokyo and other heavily populated areas currently at high levels and hospitals already under strain treating serious cases despite a state of emergency, experts have warned there is little slack in the system.
Read: Japan's Olympic chief marks pride week with LGBTQ event
Even if the country succeeds in meeting its goal of fully vaccinating all 36 million elderly by the end of July — already a week into the Games — about 70% of the population would not be inoculated. And many have dismissed the target as overly optimistic anyway.
To meet it, Japan is vowing to soon start administering 1 million doses daily. It currently is only giving 500,000 per day, already a big improvement after Prime Minister Yoshihide Suga called on military doctors and nurses and started making legal exceptions to recruit other vaccinators in order to boost the drive.
“Vaccinations under the current pace are not going to help prevent infections during the Olympics,” Tokyo Medical Association Chairman Haruo Ozaki said. “The Olympics can trigger a global spread of different variants of the virus.”
The International Olympic Committee says more than 80% of athletes and staff staying in the Olympic Village on Tokyo Bay will be vaccinated — and they are expected to remain largely in a bubble at the village and venues. On Tuesday, Japan started vaccinating athletes who will go to the Games, the Japanese Olympic Committee said.
But vaccination rates are not clear for others involved in the Games who are coming from abroad, including hard-hit regions, and experts warn that even strict rules won’t prevent all mingling, especially among non-athletes. Spectators from overseas have been barred.
Prominent medical journals have questioned the wisdom of pushing ahead with the Tokyo Games and the Asahi Shimbun — the country’s second-largest newspaper — has called for them to be canceled, reflecting widespread opposition to holding the Olympics now among the Japanese population.
But the government has said it’s determined to push ahead, with the viability of Suga’s leadership and geopolitical competition with rival Beijing, the next Olympics host, as well as the health of millions, on the line.
“By using a new weapon called vaccines and taking firm preventive measures, it is fully possible” to hold the Olympics safely, Suga told a parliamentary session Tuesday.
Officials are now desperately trying to think of ways to increase the shots at a time when medical workers are already under pressure treating COVID-19 patients. Many say they have no extra resources to help with the Olympics, if, for instance, the boiling Japanese summer causes widespread cases of heat stroke. Some local leaders in and around Tokyo have rejected the Olympics organizers’ requests to set aside beds for athletes.
Read:Torch relay for Tokyo Olympics kicks off its 121-day journey
Dr. Shigeru Omi, former World Health Organization regional director and a head of a government taskforce, said it is crucial to start inoculating younger people, who are seen as likely to spread the virus, as soon as possible.
More than three months into Japan’s vaccination campaign, only 2.7% of the population has been fully vaccinated. The country started its rollout with health care workers in mid-February, months behind many other countries because Japan required additional clinical testing here, a step many experts say was medically meaningless.
Inoculations for the elderly, who are more likely to suffer serious problems when infected, started in mid-April, but were slowed by initial supply shortages, cumbersome reservation procedures and a lack of medical workers to give shots.
But there are signs of improvement. The vaccine supply has increased and despite earlier expectations of a hesitant response to vaccines in general, senior citizens fearful of the virus are rushing to inoculation sites.
Since May 24, Japan has deployed 280 military doctors and nurses in Tokyo and the badly hit city of Osaka. More than 33,000 vaccination sites now operate across Japan, and more are coming, said Taro Kono, the minister in charge of vaccinations.
In Sumida, a district in downtown Tokyo where boxing events will be held, vaccinations for its 61,000 elderly residents began on May 10, and within two weeks, 31% of them had gotten their first shots, compared to the national average of 3.7%. Sumida is now looking to start inoculating younger people later this month, well ahead of schedule.
Close coordination among primary care doctors, hospitals and residents, as well as flexibility, have contributed to smooth progress, Sumida district spokesperson Yosuke Yatabe said.
“It’s like a factory line,” Yatabe said.
Ryuichiro Suzuki, a 21-year-old university student in Tokyo, said he is frustrated with Japan’s lagging vaccination campaign.
“I saw that some of my friends overseas have been vaccinated, but my turn won’t come until later this summer,” he said. “The risk-averse government took extra caution even when our primary goal was to get back to normal as soon as possible.”
Read: Tokyo Olympic organizers to meet March 20 on fate of overseas spectators
Kono, the vaccine minister, said more large-scale inoculation centers are getting underway, including at hundreds of college campuses and offices to start vaccinating younger people from June 21.
Beyond the concerns about the Olympics and despite the fact that Japan has seen fewer cases and deaths compared to the United States and other advanced nations, the country’s slow pace of vaccinations and its prolonged, often toothless state of emergency could also delay its economic recovery for months, said Masaya Sasaki, senior economist at the Nomura Research Institute.
And despite repeated expressions of official government confidence in the Games being safe, there are fears here of what might happen if vaccinations don’t pick up.
“The Olympics, billed as a recovery Games, can trigger a new disaster,” said Ueyama, of the Japan Doctors Union.
Close to committing $1 billion to Moderna for Covid-19 booster shot: Cipla
Seeking fast-track approvals to bring Moderna’s single-dose Covid-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty, while stating that it is close to committing over ₹1 billion as advance to the US major, sources said on Monday, reports Hindustan Times.
Commending the government for its efforts to increase the vaccine availability in the country for achieving effective protection against Covid-19, the Indian pharma giant has said its discussions with Moderna on the Covid-19 booster vaccine are nearing finalisation and for that, they are seeking the “partnership and support of the government to make this programme successful”.
Requesting the government to provide confirmation on four critical points --- exemption from price restriction, indemnification, bridging trial waiver and basic customs duty exemption, Cipla has said such an assurance will help make this significant financial commitment of more than USD 1 billion (over ₹7,250 crore) advance to Moderna for its booster vaccine in India, sources privy to the development said.
Cipla’s latest communication to the government, dated May 29, follows a high-level meeting held recently during which it was discussed that Moderna has proposed to launch a single-dose vaccine for the Indian market, for which, they were in discussion with Cipla and other Indian companies.
It was also discussed in that meeting that orders for supply of the vaccine in 2022 may be placed with Moderna expeditiously and that Cipla has evinced interest to procure 50 million doses from Moderna for 2022. It was also suggested that Cipla may be asked to submit their specific requests to the government on their request for a “confirmation from the Government of India in respect of stability in regulatory requirements/policy regime” and a decision on that can be taken thereafter expeditiously.
Taking the matter forward, Cipla has now written to the government, “It is imperative Cipla brings Moderna booster vaccines to India urgently, having immediately made available the largest portfolio of Covid-19 drugs amongst Indian pharmaceutical companies, including the state-of-the-art antibody cocktail of Casirivimab and Imdevimab.”
Stating that Moderna’s vaccine has been rated at the highest efficacy with least side effects, Cipla has told the government that it needs assurance to include Moderna booster vaccine under the Liberalised Pricing and Accelerated National Covid-19 Vaccination Strategy, announced in April and made effective from May 1.
Bangladesh sees rise in Covid infections; 41 more die
Amid the growing trend in both the Coronavirus infections and fatalities, Bangladesh logged 41 more deaths, pushing up the death toll to 12,660.
Besides, health authorities detected 1,765 new cases after testing 18,250 samples during the period.
The country’s daily death record remained below 40 since May 25 while it stayed below 50 since May 9.
With the new cases, the total caseload rose to 8,02,305, said a handout of the Directorate General of Health Services (DGHS).
The daily infection rate slightly increased to 9.47 percent from Monday’s 9.41 percent while the mortality rate remained static at 1.58 percent.
The country has so far tested 59,65,763 samples.
Read:Covid: WHO renames UK and other variants with Greek letters
The DGHS handout says 92.50% of the people infected till now have recovered, including 1,779 who tested negative during the period.
Bangladesh reported its first Coronavirus cases on March 8 last year and the first death on the 18th of that month.